Skip to main content
. 2016 Feb 22;7(14):18424–18439. doi: 10.18632/oncotarget.7575

Figure 2. Induction of trastuzumab-resistance in gastric cancer cell lines.

Figure 2

A. Trastuzumab sensitivity curves in parental cell lines evaluated by clonogenic assay. Each point indicates the mean of at least three experiments. The standard deviation never exceeded 5%. B. Percentage (median value) of BrdU-positive cells after trastuzumab treatment (100 μg/ml). Values are the mean ± SD of three independent experiments. * significance at p<0.05 by t-test. C. The induction timeline of trastuzumab resistance. Resistant cells were generated by continuous treatment with trastuzumab for more than 8 months. D. Trastuzumab sensitivity curves in resistant cell lines evaluated by clonogenic assay. Each point indicates the mean of at least three experiments. Standard deviation never exceeded 5%. E. Percentage (median value) of BrdU-positive cells after trastuzumab treatment (100 μg/ml). Values are the mean ± SD of three independent experiments. * significance at p<0.05 by t-test. F. Doubling times of parental and resistant cell lines. G. Cell cycle analysis of NCI N87 and NCI N87 HR by flow cytometry. Data are expressed as a percentage of distribution in each cell-cycle phase.